Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

SanBio (4592 JP): FY27 Guidance Reiterated, All Eyes On How Akuugo Sales Fall Through

SanBio (4592 JP): Akuugo Awaiting NHI Price Listing and Launch, SB623 Trial Progressing Well In US

SanBio Co (4592 JP): Akuugo Launch Awaited, Groundwork Being Laid for New Indications & Geographies

SanBio Co Ltd (4592 JP): International Offering Attractive, Akuugo Approval Is Next Big Trigger

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sanbio-co-ltd" target="_blank" data-smartkarma-citation="entities:24540:1" rel="noopener">SanBio Co Ltd (4592 JP)</a> reported lower operating loss (~¥953.3M) in Q1FY27 as R&amp;D expenses decreased. Net loss witnessed narrowing too.</li>
<li>Akuugo received the NHI price listing in May 2026, and was eventually launched in June. SanBio will accelerate a project to expand Akuugo’s current indication for traumatic brain injury globally.  </li>
<li>FY27 guidance reiterated with revenue expected to be ¥396M. SanBio remains a risky bet with probability of a high return going up with every milestone.</li>
</ul>



SanBio Co Ltd (4592 JP) reported lower operating loss (~¥953.3M) in Q1FY27 as R&amp;D expenses decreased. Net loss witnessed narrowing too.
Akuugo received the NHI price listing in May 2026, and was eventually launched in June. SanBio will accelerate a project to expand Akuugo’s current indication for traumatic brain injury globally.  
FY27 guidance reiterated with revenue expected to be ¥396M. SanBio remains a risky bet with probability of a high return going up with every milestone.


SanBio (4592 JP): Q1 Losses Narrow, NHI Price Listing and Akuugo Launch Done, Guidance Reiterated